Identification | Back Directory | [Name]
Irbinitinib | [CAS]
937263-43-9 | [Synonyms]
ONT-380) 6-diaMine N4-(4-([1 Irbinitinib 4-diMethyl-4 (R)-N6-(4-Methyl-4 Irbinitinib(ARRY380) 5-dihydrooxazol-2-yl)quinazoline-4 5-a]pyridin-7-yloxy)-3-Methylphenyl)-N6-(4 5-dihydrooxazol-2-yl)-N4-(3-Methyl-4-(thiazol-2-ylMethoxy)phenyl)quinazoline-4 N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]- | [EINECS(EC#)]
200-001-8 | [Molecular Formula]
C26H24N8O2 | [MDL Number]
MFCD22380467 | [MOL File]
937263-43-9.mol | [Molecular Weight]
480.521 |
Chemical Properties | Back Directory | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:1.0(Max Conc. mg/mL);2.08(Max Conc. mM) DMSO:49.0(Max Conc. mg/mL);101.97(Max Conc. mM) DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.69(Max Conc. mM) | [form ]
A crystalline solid | [pka]
6.61±0.70(Predicted) | [InChIKey]
SDEAXTCZPQIFQM-UHFFFAOYSA-N | [SMILES]
N1=C2C(C=C(NC3=NC(C)(C)CO3)C=C2)=C(NC2=CC=C(OC3C=CN4N=CN=C4C=3)C(C)=C2)N=C1 |
Questions and Answers (Q&A) | Back Directory | [Description]
Irbinitinib is also known as ARRY-380 or Tucatinib. ARRY-380 is an orally inhibitor of human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. It selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Therefore, ARRY-380 may be an alternative treatmentmethod for the treatment of HER2+ cancers.
| [References]
Lee, P., et al. "In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab." Cancer Research 69.24 Supplement(2009):5104-5104.
Moulder, S. L., et al. "Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation." Molecular Cancer Therapeutics 10.Supplement 1(2011):A143-A143.
Dinkel, Victoria, et al. "Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice." Cancer Research 72.8 Supplement(2012).
|
Hazard Information | Back Directory | [Characteristics]
Year of discovery: 2006 Year of introduction: 2020 Discovered by: Array BioPharma Developed by: Array BioPharma Primary targets: HER2 Binding type: I/II Class: receptor tyrosine kinase Treatment: HER2-positive breast cancer Other names: ONT-380, ARRY-380 Oral bioavailability = not reported Elimination half-life = 5.4 hours Protein binding = 97% | [Uses]
N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine is a novel?diarylamine ErbB inhibitor. | [storage]
Store at -20°C | [Mode of action]
Tucatinib binds to tyrosine kinase (an enzyme) of HER2, reducing PI3-kinase and MAP-kinase signaling. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone. |
|
|